ES2721280T3 - Nuevos inhibidores de la FYN quinasa - Google Patents

Nuevos inhibidores de la FYN quinasa Download PDF

Info

Publication number
ES2721280T3
ES2721280T3 ES15825936T ES15825936T ES2721280T3 ES 2721280 T3 ES2721280 T3 ES 2721280T3 ES 15825936 T ES15825936 T ES 15825936T ES 15825936 T ES15825936 T ES 15825936T ES 2721280 T3 ES2721280 T3 ES 2721280T3
Authority
ES
Spain
Prior art keywords
cycloalkyl
alkyl
independently selected
alkoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15825936T
Other languages
English (en)
Inventor
Roberto Artusi
Gianfranco Caselli
Lucio Rovati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rottapharm Biotech SRL
Original Assignee
Rottapharm Biotech SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Biotech SRL filed Critical Rottapharm Biotech SRL
Application granted granted Critical
Publication of ES2721280T3 publication Critical patent/ES2721280T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de Fórmula (I):**Fórmula** en la que: A se selecciona entre fenilo, anillo heterocíclico de 5-6 miembros que contiene uno o más heteroátomos seleccionados de N, S y O y cicloalquilo(C5-C7), donde dicho fenilo está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, trifluorometilo, trifluorometoxi, alquilo (C1-C4), alcoxi (C1-C3), cicloalquilo (C3- C6), cicloalquiloxi (C3-C6), nitro, amino, hidroxilo, ciano, carboxamida, sulfonamida, metanosulfonilo, dicho anillo heterocíclico de 5-6 miembros es un heteroarilo de 5-6 miembros opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halógeno, trifluorometilo, trifluorometoxi, alquilo (C1- C4), alcoxi (C1-C3), cicloalquilo (C3-C6), cicloalquiloxi (C3-C6), nitro, amino, hidroxilo, ciano, carboxamida, sulfonamida, metansulfonilo o un anillo heterocíclico de 5 miembros opcionalmente sustituido con alquilo (C1-C3); dicho cicloalquilo (C5-C7) está opcionalmente sustituido independientemente con uno o dos alquilo (C1-C4); B se selecciona independientemente de -CONH-, -NHCO-, -SO2NH-, -NHCONH-; W es un grupo fenilo o heteroarilo que comprende uno o dos heteroátomos seleccionados de N, O y S, siendo dicho fenilo o dicho heteroarilo opcionalmente sustituido independientemente con uno o dos alquilo (C1-C4), alcoxi (C1-C3), cicloalquilo (C3-C6), cicloalquiloxi (C3-C6); R y R1 se seleccionan independientemente de un grupo que consiste en H, alquilo (C1-C3) y alcoxi (C1-C3); m es 2; n es 1; X es N; Y se selecciona independientemente entre H, CH3, CH2-OH, CN; G es un grup
ES15825936T 2015-03-18 2015-12-23 Nuevos inhibidores de la FYN quinasa Active ES2721280T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159604.6A EP3070084A1 (en) 2015-03-18 2015-03-18 New fyn kinase inhibitors
PCT/EP2015/081124 WO2016146220A1 (en) 2015-03-18 2015-12-23 New fyn kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2721280T3 true ES2721280T3 (es) 2019-07-30

Family

ID=52779492

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15825936T Active ES2721280T3 (es) 2015-03-18 2015-12-23 Nuevos inhibidores de la FYN quinasa

Country Status (7)

Country Link
US (1) US10125121B2 (es)
EP (2) EP3070084A1 (es)
JP (1) JP6467059B2 (es)
CN (1) CN107406428B (es)
CA (1) CA2979758C (es)
ES (1) ES2721280T3 (es)
WO (1) WO2016146220A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017212018A1 (en) * 2016-06-10 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
CN112204025B (zh) 2018-05-29 2022-05-31 瑟赛治疗公司 用于治疗疼痛的化合物，包含其的组合物以及使用其的方法
JP2022531453A (ja) 2019-05-10 2022-07-06 セルシィ セラピューティクス，インコーポレーテッド チアゾリン抗痛覚過敏薬の製造方法及び多形体
WO2021115560A1 (en) * 2019-12-09 2021-06-17 Rottapharm Biotech S.R.L. New fyn and vegfr2 kinase inhibitors
CN111171064B (zh) * 2020-01-09 2022-09-16 上海健康医学院 氮杂氟硼二吡咯类化合物及其制备方法和作为Fyn激酶抑制剂的应用
JP2024518711A (ja) * 2021-04-12 2024-05-02 エーツーエー ファーマシューティカルズ インコーポレーテッド 癌を処置するための組成物及び方法
TW202400575A (zh) 2022-03-24 2024-01-01 美商Ａ２Ａ製藥公司 治療癌症的組合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002294A (es) * 2000-09-15 2005-09-08 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
WO2003078426A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazine as inhibitors of protein kinases
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP2170867A1 (en) * 2007-06-15 2010-04-07 Irm Llc Protein kinase inhibitors and methods for using thereof

Also Published As

Publication number Publication date
CN107406428B (zh) 2021-06-04
WO2016146220A1 (en) 2016-09-22
EP3271348B1 (en) 2019-01-30
EP3070084A1 (en) 2016-09-21
JP6467059B2 (ja) 2019-02-06
JP2018507857A (ja) 2018-03-22
US20180111919A1 (en) 2018-04-26
US10125121B2 (en) 2018-11-13
EP3271348A1 (en) 2018-01-24
CN107406428A (zh) 2017-11-28
CA2979758C (en) 2018-12-04
CA2979758A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
ES2721280T3 (es) Nuevos inhibidores de la FYN quinasa
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
CO6210721A2 (es) Acilaminopirazoles como inhibidores de fgfr
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
CU24393B1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
PE20131143A1 (es) Nuevas aminopirazoloquinazolinas
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
EA202091893A1 (ru) Новые кристаллические формы
CU24621B1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
AR096246A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
PE20211472A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
AR073369A1 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
EA202191104A1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
EA201171062A1 (ru) Алкиламидные соединения и их применение
RU2021109549A (ru) ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
PE20070829A1 (es) Inhibidores cetp heterociclicos
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине
PE20071034A1 (es) Compuestos heterociclicos como inhibidores de cetp